比较评估成人急性髓系白血病强化化疗适宜性的评分系统——大西部抗白血病(GOAL)研究
该研究在法国五家学术中心连续纳入428例接受常规诱导化疗的成人急性髓系白血病(AML)患者,比较多种评分系统对强化化疗适宜性的评估效能。各评分系统虽能识别28天和56天死亡率升高的患者亚组,但预测准确性有限(C统计量0.61–0.71),基于近期随机试验标准判定的104例(24%)不适合强化化疗患者,其结局与其余324例患者相似,且判别力低(C统计量0.50–0.57)。作者认为现有评分系统准确性相对有限,临床决策中应谨慎使用。
要点
- 各评分系统可识别早期死亡率升高的AML患者亚组,但预测准确性有限(C统计量0.61–0.71)。
- 基于随机试验标准判定的104例(24%)不适合强化化疗患者,其28天、56天死亡率、无事件生存期和总生存期与其余324例患者无显著差异。
- 现有评分系统判别力低(C统计量0.50–0.57),临床决策中应谨慎使用。
核心结论
- 现有用于识别强化AML化疗后早期死亡风险升高和生存期缩短的方法准确性相对有限,临床决策中使用现有评分系统应谨慎。
研究设计与样本
- 在法国五家学术中心连续纳入428例接受常规诱导化疗的成人AML患者,比较多种评分系统的评估效能。
主要发现
- 各评分系统均能识别28天和56天死亡率升高的患者亚组,但预测准确性总体有限,C统计量为0.61至0.71。
- 总生存期预测更为有限,仅局限于包含AML相关参数的评分系统。
- 基于近期随机试验标准判定的104例(24%)不适合强化化疗患者,其结局与其余324例患者相似:28天死亡率比值比(OR)=1.88,P=0.2;56天死亡率OR=1.71,P=0.21;无事件生存期风险比(HR)=1.08,P=0.6;总生存期HR=1.25,P=0.14。
- 上述判定的判别力低:28天死亡率、56天死亡率、无事件生存期和总生存期的C统计量分别为0.57、0.56、0.50和0.52。
关键数值与推荐
- 各评分系统预测28天和56天死亡率的C统计量为0.61至0.71。
- 基于随机试验标准判定的不适合强化化疗患者(104例,24%)与其余患者(324例)比较:28天死亡率OR=1.88(P=0.2),56天死亡率OR=1.71(P=0.21),无事件生存期HR=1.08(P=0.6),总生存期HR=1.25(P=0.14)。
- 上述判定的C统计量:28天死亡率0.57,56天死亡率0.56,无事件生存期0.50,总生存期0.52。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several scoring systems have been developed to assess suitability of individual patients for intensive acute myeloid leukemia (AML) therapy. We sought to compare the performance of these scores in a cohort of 428 consecutive adults with AML who received conventional induction chemotherapy in five academic centers in France. All scoring systems identified a subset of patients with increased 28 and 56-day mortality although the prediction accuracy was overall limited with C-statistics of ranging from 0.61 to 0.71 Overall survival (OS) prediction was more limited and restricted to scoring systems that include AML-related parameters. The outcome of 104 patients (24%) considered unsuitable for intensive chemotherapy based on criteria used in recent randomized trials was similar to that of the other 324 patients (28-day mortality, odds ratio [OR] = 1.88, P = 0.2; 56-day mortality, OR = 1.71, P = 0.21; event-free survival, hazard ratio [HR] = 1.08, P = 0.6; OS, HR = 1.25, P = 0.14) with low discrimination (C-statistic: 0.57, 0.56, 0.50, and 0.52 for 28-day, 56-day mortality, EFS, and OS, respectively). Together, our findings indicate that the accuracy of currently available approaches to identify patients at increased risk of early mortality and shortened survival after intensive AML therapy is relatively limited. Caution regarding the use of available scoring systems should be warranted in clinical decision-making.
引用
- Desprez C, Riou J, Peterlin P, et al. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study. Leukemia. 2022. PMID: 35962057. doi:10.1038/s41375-022-01677-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。